Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
about
Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C.Novel therapies for renal cell carcinoma.Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitroImmunotherapy of metastatic renal cell cancer.Novel therapies for renal cell carcinoma--an update.A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjectsUse of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis CPharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteersNovel delivery systems for interferons.Biotherapeutic bioanalysis: a multi-indication case study review.Antiviral activity of the interferon α family: biological and pharmacological aspects of the treatment of chronic hepatitis C.Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.Cognitive effects of pegylated interferon in individuals with primary brain tumors.Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.
P2860
Q33392904-6220EF01-6358-465F-834B-3D5F1008E2B1Q34262438-D0174707-1AC4-4C18-9AD4-BCBF6E5A3A9CQ34481460-9827CEBF-6C7E-4452-A40B-49F32634F1F5Q34526617-16874835-E5FA-4801-875E-450A1F03E33FQ34645498-019022EF-5000-42AF-8EB4-2D525C49DF10Q34849167-FB994D47-BB37-4629-842C-A99C82D364C8Q35094669-C2951703-57D3-4E90-BC1E-C5F8DF4DB207Q35286136-2BDE23E6-3830-472F-99EC-F9D4E3915202Q35640461-690DCCAF-4DEB-4C40-B220-AAB715D66F81Q36214486-AD7823A3-F7A8-437D-AB63-34F1109DC52CQ36937971-8654CF5F-3456-413D-9C8C-6E1057E17F0FQ37854629-45825B7D-C3A8-4622-8E28-4624B8ECF573Q38076757-1AB0AF2C-1F2F-4821-B81C-2AF05173636CQ42841419-DDEC154F-D9E7-4846-B1E9-78EC277F299EQ43039959-07252994-86B5-4B2E-A321-755D05D1FBC8Q47683710-C6753B6B-2E06-4615-9E93-AC0D854FA409Q52838661-41670D7D-6407-44F7-89FC-E98E8C5623D8
P2860
Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Phase I trial of 40-kd branche ...... advanced renal cell carcinoma.
@ast
Phase I trial of 40-kd branche ...... advanced renal cell carcinoma.
@en
type
label
Phase I trial of 40-kd branche ...... advanced renal cell carcinoma.
@ast
Phase I trial of 40-kd branche ...... advanced renal cell carcinoma.
@en
prefLabel
Phase I trial of 40-kd branche ...... advanced renal cell carcinoma.
@ast
Phase I trial of 40-kd branche ...... advanced renal cell carcinoma.
@en
P2093
P1476
Phase I trial of 40-kd branche ...... advanced renal cell carcinoma.
@en
P2093
K Rittweger
L Hooftman
M Ginsberg
R J Motzer
P304
P356
10.1200/JCO.2001.19.5.1312
P407
P577
2001-03-01T00:00:00Z